Leap Therapeutics (NASDAQ:LPTX) Rating Lowered to “Neutral” at Robert W. Baird

Robert W. Baird lowered shares of Leap Therapeutics (NASDAQ:LPTXFree Report) from an outperform rating to a neutral rating in a research note published on Wednesday morning, MarketBeat Ratings reports. The firm currently has $1.25 target price on the stock, down from their previous target price of $9.00.

Separately, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a report on Thursday, January 16th.

View Our Latest Analysis on LPTX

Leap Therapeutics Price Performance

Shares of LPTX stock opened at $0.57 on Wednesday. The stock’s fifty day moving average price is $2.82 and its 200 day moving average price is $2.75. Leap Therapeutics has a 1-year low of $0.55 and a 1-year high of $4.79. The company has a market cap of $21.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.17.

Hedge Funds Weigh In On Leap Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valence8 US LP purchased a new stake in Leap Therapeutics during the 3rd quarter valued at about $48,000. HighTower Advisors LLC purchased a new stake in Leap Therapeutics in the third quarter valued at approximately $65,000. HB Wealth Management LLC increased its holdings in Leap Therapeutics by 103.2% in the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after buying an additional 26,150 shares during the period. Key Client Fiduciary Advisors LLC raised its position in Leap Therapeutics by 13.0% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after buying an additional 37,067 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares during the period. Hedge funds and other institutional investors own 30.46% of the company’s stock.

About Leap Therapeutics

(Get Free Report)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Featured Stories

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.